Monkeypox Vaccine and Treatment Market Size & Growth Forecast 2027–2036, By Segments (Route of Administration, Product, Gender, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Monkeypox Vaccine and Treatment Market size was worth USD 256.71 million in 2026 and is expected to grow at a 9.65% CAGR between 2027 and 2036, reaching USD 644.95 million by 2036. The industry revenue for 2027 is assessed at USD 277.58 million.
Get more details on this report
Request Free Sample ReportMonkeypox Vaccine and Treatment Market Intelligence Snapshot
Regional Market Dynamics
- North America captured 42.40% of the market in 2026, supported by strong vaccine procurement systems, advanced healthcare infrastructure, efficient public health response, and established pharmaceutical capabilities.
- Asia Pacific is forecast to grow at an 11.31% CAGR, fueled by stronger disease surveillance, expanding healthcare access, improved outbreak preparedness, and growing vaccine and treatment procurement.
Segment Momentum
- Drugs held a 67.9% share in 2026 because they remain central to managing active infections, supporting routine clinical treatment and patient care during disease outbreaks.
- Vaccines are expanding fastest as disease-control strategies increasingly emphasize prevention, supporting broader immunization efforts and stronger public health preparedness against future outbreaks.
Market Expansion Drivers
- Large-scale government vaccination campaigns accelerating outbreak containment and immunization coverage.
- Emergency use authorizations and accelerated regulatory approvals enabling rapid vaccine deployment.
- Strengthening global disease surveillance and outbreak preparedness programs improving response coordination.
Leading Market Participants
- Major companies in the monkeypox vaccine and treatment market include Bavarian Nordic A/S (Denmark), SIGA Technologies, Inc. (United States), Chimerix, Inc. (United States), Emergent BioSolutions Inc. (United States), Gilead Sciences, Inc. (United States), Pfizer Inc. (United States), Moderna, Inc. (United States), Merck & Co., Inc. (United States), BioNTech SE (Germany), Tonix Pharmaceuticals Holding Corp. (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 256.71 million
- 2027 Estimated Market Size: USD 277.58 million.
- Projected Market Size: USD 644.95 million by 2036
- Growth Forecast: 9.65% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Oral (Route of Administration) | Drugs (Product) | Male (Gender) | Hospitals (End-use)
- Emerging Opportunity Segment: Injectable (Route of Administration) | Vaccine (Product) | Female (Gender) | Specialty Clinics (End-use)
Market Growth Drivers and Industry Trends
Large-scale government vaccination campaigns accelerating outbreak containment and immunization coverage
Government-led vaccination initiatives can substantially increase access to preventive interventions when outbreaks create an urgent need to protect vulnerable populations and limit transmission. The monkeypox vaccine and treatment market is supported by coordinated immunization campaigns because centralized procurement, public-health distribution networks, and targeted vaccination programs can accelerate the deployment of vaccines among populations considered at elevated risk. These programs also help integrate vaccination into broader outbreak-control strategies, allowing health authorities to prioritize available doses according to epidemiological conditions and healthcare requirements. Increased public-health activity surrounding vaccination can further strengthen demand for related medical countermeasures and distribution capabilities as authorities work to maintain adequate preparedness during periods of heightened transmission.
Emergency use authorizations and accelerated regulatory approvals enabling rapid vaccine deployment
Regulatory mechanisms designed for public-health emergencies can shorten the pathway between the evaluation of medical countermeasures and their deployment when conventional timelines are unsuitable for rapidly developing outbreaks. For the monkeypox vaccine and treatment market, emergency authorizations can facilitate earlier access to vaccines and therapies by allowing health authorities to respond more quickly to evolving disease conditions. Accelerated review processes can also provide healthcare systems with additional treatment and prevention options while maintaining required assessments of product quality, safety, and effectiveness. The resulting ability to introduce or expand the use of approved countermeasures supports procurement activity among public-health agencies and healthcare providers responding to outbreak-related demand.
Strengthening global disease surveillance and outbreak preparedness programs improving response coordination
Expanded disease surveillance is improving the ability of public-health authorities to identify emerging outbreaks, monitor transmission patterns, and coordinate interventions across healthcare networks. These preparedness efforts support the monkeypox vaccine and treatment market by encouraging governments and health organizations to maintain access to vaccines, therapeutics, diagnostic capabilities, and associated response infrastructure before disease activity reaches critical levels. Improved information sharing between surveillance systems can also help authorities identify populations requiring targeted interventions and coordinate procurement or distribution according to changing epidemiological conditions. Preparedness planning increasingly emphasizes maintaining flexible response capabilities, including mechanisms for mobilizing medical countermeasures when new cases or localized outbreaks are detected.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Large-scale government vaccination campaigns accelerating outbreak containment and immunization coverage | 2.30% | High | North America, Europe | High | Near Term |
| Emergency use authorizations and accelerated regulatory approvals enabling rapid vaccine deployment | 2.00% | High | North America, Europe | High | Near Term |
| Strengthening global disease surveillance and outbreak preparedness programs improving response coordination | 1.60% | High | Global | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America dominated the monkeypox vaccine and treatment market with a 42.40% share in 2026, supported by advanced public health infrastructure, established infectious disease management capabilities, and strong preparedness for emerging health threats. Effective healthcare delivery systems facilitate access to vaccines and therapeutic interventions, while public health awareness and surveillance capabilities support timely responses to infectious disease risks. Continued emphasis on preparedness and medical countermeasures reinforces regional market strength.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing region for the monkeypox vaccine and treatment market, driven by expanding healthcare capacity, strengthening disease surveillance, and increasing preparedness for infectious disease outbreaks. Improvements in public health infrastructure are supporting broader access to preventive and therapeutic solutions, while greater awareness of emerging infectious diseases is encouraging investment in response capabilities. Growing healthcare modernization across the region is further supporting market development.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Coordinated Public Health ResponseGermany is focusing on integrating vaccination and therapeutic access within established infectious disease preparedness frameworks. German authorities continue to support monitoring programs and healthcare provider awareness to strengthen outbreak management capabilities.
France 🇫🇷
Preventive Immunization FocusFrance is maintaining emphasis on preventive vaccination strategies and the availability of therapeutic options for vulnerable groups. The French market is shaped by continued public health planning and efforts to ensure rapid intervention capabilities during case clusters.
Italy 🇮🇹
Healthcare Response CapacityItaly is prioritizing preparedness planning and healthcare coordination to manage potential mpox outbreaks effectively. Italian health authorities are focusing on securing vaccine access and reinforcing clinical protocols for diagnosis, treatment, and patient management.
Japan 🇯🇵
Targeted Containment MeasuresJapan is emphasizing early detection and targeted immunization strategies to limit the spread of mpox cases. The market in Japan is centered on maintaining access to vaccines and treatments while reinforcing preparedness across healthcare institutions.
South Korea 🇰🇷
Surveillance-Led ReadinessSouth Korea is reinforcing disease surveillance and response mechanisms to support timely deployment of vaccines and treatments. Healthcare authorities in South Korea are prioritizing coordinated preparedness measures and strengthening public health communication around mpox risks.
United States 🇺🇸
Preparedness Stockpiling StrategyThe U.S. continues to prioritize vaccine procurement and treatment readiness to support rapid response capabilities during mpox outbreaks. Public health agencies in the U.S. are emphasizing surveillance, strategic reserves, and targeted vaccination programs for at-risk populations.
Segment Leadership and Growth Trends
Monkeypox Vaccine and Treatment Market Share (%), by Route of Administration, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportRoute of Administration Segment Analysis: Oral (Largest Segment) vs Injectable (Fastest-Growing Segment)
The oral segment held the largest share of the monkeypox vaccine and treatment market in 2026, accounting for 63.05% of the market. Oral administration offers ease of use, convenience, and greater suitability for treatment settings where straightforward dosing can support patient adherence. Its accessibility also makes oral therapies practical for broader patient management, particularly when treatment needs to be delivered without specialized administration procedures. The established role of orally administered treatments in infectious disease management further supports their continued adoption.
Injectable administration is gaining momentum as healthcare systems place greater emphasis on vaccination and rapid delivery of therapies during infectious disease outbreaks. Injectable products can provide a direct and controlled route for administering vaccines and treatments, making them relevant when rapid immune protection or clinically supervised administration is required. Growing preparedness for emerging infectious diseases and the need for effective outbreak-response tools are supporting increased attention toward injectable options.
Product Segment Analysis: Drugs (Largest Segment) vs Vaccine (Fastest-Growing Segment)
In the monkeypox vaccine and treatment market, the drugs segment represented the largest share in 2026 at 67.9%. Its strong position reflects the continuing need for therapeutic interventions to manage symptoms and complications associated with infection. Availability of established treatment approaches, combined with the need for targeted disease management among diagnosed patients, supports demand for drug-based products. The segment also benefits from healthcare providers' emphasis on treating active infections and managing patient outcomes.
The vaccine segment is expanding rapidly as public-health preparedness increasingly emphasizes prevention alongside treatment. Vaccination can play an important role in reducing infection risk and limiting transmission, particularly when health authorities respond to outbreaks or heightened disease surveillance. Greater awareness of preventive healthcare, preparedness planning, and the importance of immunization strategies is strengthening the role of vaccines within the broader monkeypox management landscape.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Route of Administration | Oral, Injectable | Oral | Injectable |
| Product | Vaccine, Drugs, Vaccinia Immune Globulin (VIG) | Drugs | Vaccine |
| Gender | Male, Female, Others | Male | Female |
| End-use | Hospitals, Specialty Clinics, Others | Hospitals | Specialty Clinics |
Competitive Landscape and Market Positioning
Top players in the monkeypox vaccine and treatment market:
1. Bavarian Nordic A/S (Denmark)
2. SIGA Technologies Inc. (United States)
3. Chimerix Inc. (United States)
4. Emergent BioSolutions Inc. (United States)
5. Gilead Sciences Inc. (United States)
6. Pfizer Inc. (United States)
7. Moderna Inc. (United States)
8. Merck & Co. Inc. (United States)
9. BioNTech SE (Germany)
10. Tonix Pharmaceuticals Holding Corp. (United States)
The monkeypox vaccine and treatment market is shaped by accelerated medical research and rapid therapeutic development. R&D investments are focusing on improving vaccine efficacy and treatment responsiveness. Collaborative efforts with health organizations are enabling faster deployment and response readiness. Regulatory pathways are also influencing speed of approval and distribution.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Bavarian Nordic A/S (Denmark) | |||||||
| SIGA Technologies Inc. (United States) | |||||||
| Chimerix Inc. (United States) | |||||||
| Emergent BioSolutions Inc. (United States) | |||||||
| Gilead Sciences Inc. (United States) | |||||||
| Pfizer Inc. (United States) | |||||||
| Moderna Inc. (United States) | |||||||
| Merck & Co. Inc. (United States) | |||||||
| BioNTech SE (Germany) | |||||||
| Tonix Pharmaceuticals Holding Corp. (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| KM Biologics | Aug-22 | Japan approved KM Biologics’ LC16 KMB vaccine for monkeypox disease, expanding available immunization options for orthopoxvirus infections. The approval strengthens national preparedness and supports broader vaccine deployment strategies for emerging infectious disease control and outbreak response capabilities. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Monkeypox Vaccine and Treatment Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Indication | Preventive Vaccination, Post-Exposure Prophylaxis, Active Infection Treatment |
| Distribution Channel | Government Procurement, Hospital & Clinic Supply, Retail & Specialty Pharmacies, Online Pharmacies |
| Purchaser Type | Government & Public Health Agencies, Healthcare Institutions, Private Organizations, Individual Consumers |
Monkeypox Vaccine and Treatment Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Global Preparedness and Response Strategy |
|
| Vaccine Stockpiling and Procurement Priorities |
|
| Outbreak Scenario and Treatment Access Assessment |
|
Need a different cut of the data?
Request Custom ResearchHow much revenue does the monkeypox vaccine and treatment market generate?
How is the monkeypox vaccine and treatment industry size expected to evolve during the forecast period?
How are large-scale vaccination campaigns influencing demand in the monkeypox vaccine and treatment market?
How do emergency use authorizations impact commercialization in this market?
Which product segment led the monkeypox vaccine and treatment market in 2026?
Why are vaccines the fastest-growing product segment in the monkeypox vaccine and treatment market?
Why does North America lead the monkeypox vaccine and treatment market?
What is driving monkeypox vaccine and treatment market growth in Asia Pacific?
What are the prominent companies operating in the monkeypox vaccine and treatment landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization